Cargando…

A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing

Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin-Zhu, Guo, Rong, Zhao, Cong, Xu, Jing, Song, Hang, Yu, Hua, Pilarsky, Christian, Nainu, Firzan, Li, Jing-Quan, Zhou, Xin-Ke, Zhang, Jian-Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353945/
https://www.ncbi.nlm.nih.gov/pubmed/35935840
http://dx.doi.org/10.3389/fphar.2022.939090
_version_ 1784762963914129408
author Chen, Xin-Zhu
Guo, Rong
Zhao, Cong
Xu, Jing
Song, Hang
Yu, Hua
Pilarsky, Christian
Nainu, Firzan
Li, Jing-Quan
Zhou, Xin-Ke
Zhang, Jian-Ye
author_facet Chen, Xin-Zhu
Guo, Rong
Zhao, Cong
Xu, Jing
Song, Hang
Yu, Hua
Pilarsky, Christian
Nainu, Firzan
Li, Jing-Quan
Zhou, Xin-Ke
Zhang, Jian-Ye
author_sort Chen, Xin-Zhu
collection PubMed
description Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progression, and treatment prognosis of malignant tumors are closely related to genetic and gene mutation. CRISPR/Cas9 has emerged as a powerful method for making changes to the genome, which has extensively been applied in various cell lines. Establishing the cell and animal models by CRISPR/Cas9 laid the foundation for the clinical trials which possibly treated the tumor. CRISPR-Cas9-mediated genome editing technology brings a great promise for inhibiting migration, invasion, and even treatment of tumor. However, the potential off-target effect limits its clinical application, and the effective ethical review is necessary. The article reviews the molecular mechanisms of CRISPR/Cas9 and discusses the research and the limitation related to cancer clinical trials.
format Online
Article
Text
id pubmed-9353945
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93539452022-08-06 A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing Chen, Xin-Zhu Guo, Rong Zhao, Cong Xu, Jing Song, Hang Yu, Hua Pilarsky, Christian Nainu, Firzan Li, Jing-Quan Zhou, Xin-Ke Zhang, Jian-Ye Front Pharmacol Pharmacology Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progression, and treatment prognosis of malignant tumors are closely related to genetic and gene mutation. CRISPR/Cas9 has emerged as a powerful method for making changes to the genome, which has extensively been applied in various cell lines. Establishing the cell and animal models by CRISPR/Cas9 laid the foundation for the clinical trials which possibly treated the tumor. CRISPR-Cas9-mediated genome editing technology brings a great promise for inhibiting migration, invasion, and even treatment of tumor. However, the potential off-target effect limits its clinical application, and the effective ethical review is necessary. The article reviews the molecular mechanisms of CRISPR/Cas9 and discusses the research and the limitation related to cancer clinical trials. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353945/ /pubmed/35935840 http://dx.doi.org/10.3389/fphar.2022.939090 Text en Copyright © 2022 Chen, Guo, Zhao, Xu, Song, Yu, Pilarsky, Nainu, Li, Zhou and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Xin-Zhu
Guo, Rong
Zhao, Cong
Xu, Jing
Song, Hang
Yu, Hua
Pilarsky, Christian
Nainu, Firzan
Li, Jing-Quan
Zhou, Xin-Ke
Zhang, Jian-Ye
A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
title A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
title_full A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
title_fullStr A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
title_full_unstemmed A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
title_short A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
title_sort novel anti-cancer therapy: crispr/cas9 gene editing
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353945/
https://www.ncbi.nlm.nih.gov/pubmed/35935840
http://dx.doi.org/10.3389/fphar.2022.939090
work_keys_str_mv AT chenxinzhu anovelanticancertherapycrisprcas9geneediting
AT guorong anovelanticancertherapycrisprcas9geneediting
AT zhaocong anovelanticancertherapycrisprcas9geneediting
AT xujing anovelanticancertherapycrisprcas9geneediting
AT songhang anovelanticancertherapycrisprcas9geneediting
AT yuhua anovelanticancertherapycrisprcas9geneediting
AT pilarskychristian anovelanticancertherapycrisprcas9geneediting
AT nainufirzan anovelanticancertherapycrisprcas9geneediting
AT lijingquan anovelanticancertherapycrisprcas9geneediting
AT zhouxinke anovelanticancertherapycrisprcas9geneediting
AT zhangjianye anovelanticancertherapycrisprcas9geneediting
AT chenxinzhu novelanticancertherapycrisprcas9geneediting
AT guorong novelanticancertherapycrisprcas9geneediting
AT zhaocong novelanticancertherapycrisprcas9geneediting
AT xujing novelanticancertherapycrisprcas9geneediting
AT songhang novelanticancertherapycrisprcas9geneediting
AT yuhua novelanticancertherapycrisprcas9geneediting
AT pilarskychristian novelanticancertherapycrisprcas9geneediting
AT nainufirzan novelanticancertherapycrisprcas9geneediting
AT lijingquan novelanticancertherapycrisprcas9geneediting
AT zhouxinke novelanticancertherapycrisprcas9geneediting
AT zhangjianye novelanticancertherapycrisprcas9geneediting